Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

被引：0
|
作者：
Nicola Ferrante
Daniela Ritrovato
Rossella Bitonti
Gianluca Furneri
机构：
[1] Novartis Farma S.p.A,
[2] EBMA Consulting,undefined
来源：
BMC Health Services Research | / 22卷
关键词：
Brolucizumab; Neovascular age-related macular degeneration; nAMD; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
    Luis Javier Hernández-Pastor
    Ana Ortega
    Alfredo García-Layana
    Joaquín Giráldez
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248 : 467 - 476
  • [32] Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
    Javier Hernandez-Pastor, Luis
    Ortega, Ana
    Garcia-Layana, Alfredo
    Giraldez, Joaquin
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (04) : 467 - 476
  • [33] COST-EFFECTIVENESS OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CANADA
    Buhrer, C.
    Paulo, T.
    Diles, D.
    VALUE IN HEALTH, 2022, 25 (12) : S111 - S112
  • [34] Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan
    Yanagi, Yasuo
    Fukuda, Aya
    Barzey, Victor
    Adachi, Kenji
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) : 204 - 212
  • [35] Changes in blood flow one year after treatment with aflibercept or brolucizumab for neovascular age-related macular degeneration
    Yamada, Takeyasu
    Osaka, Rie
    Akimitsu, Junichiro
    Kojima, Hirokazu
    Miyoshi, Yukiko
    Yamashita, Ayana
    Nakano, Yuki
    Suzuma, Kiyoshi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [36] COST-EFFECTIVENESS ANALYSIS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN CHINA
    Zhao, M.
    Feng, W.
    Zhang, L.
    Ke, X.
    Zhang, W.
    Xuan, J.
    VALUE IN HEALTH, 2015, 18 (07) : A421 - A421
  • [37] Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis
    Siddiqui, Zasim Azhar
    Dhumal, Trupti
    Patel, Jay
    LeMasters, Traci
    Almony, Arghavan
    Kamal, Khalid M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (12): : 1350 - 1364
  • [38] The cost-effectiveness of treatment of age-related macular degeneration: a review
    Kymes, Steven N.
    MINERVA MEDICA, 2009, 100 (01) : 69 - 77
  • [39] NEOVASCULAR AGE RELATED MACULAR DEGENERATION (NAMD): THE EFFECT OF AFLIBERCEPT TREATMENT ON CHOROIDAL THICKNESS IN REFRACTORY NAMD PATIENTS
    Wijeyakumar, Wijeyanthy
    Syed, Adil
    Hong, Thomas
    Broadhead, Geoffrey K.
    Zhu, Meidong
    Chang, Andrew A.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 : 124 - 125
  • [40] Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients
    Sanjay Kumar Mishra
    Pradeep Kumar
    Srishti Khullar
    Amrita Joshi
    Alok Sati
    Sonali Vinay Kumar
    Deepesh Unni
    Atul Kumar
    International Journal of Retina and Vitreous, 8
12345